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Abstract Article Info 
Introduction: Plasma microRNAs (miRNAs) are biological markers that have been extensively studied in 
cancer, including nasopharyngeal cancer (NPC). The clinical significance of miRNA in NPC patients in 
Indonesia has never been studied. 
Objective: This study was aimed to know the expression of plasma miRNAs in NPC patients (miR-21, miR-29c, miR-
141dan miR-BART7) and their relationship with clinicopathological characteristics and treatment response.  
Method: This was a cohort, longitudinal study among locally advanced NPC patients (stage IIB-IVB) in 
Dharmais Cancer Hospital, Jakarta. miRNA expression was assayed using quantitative real-time polymerase 
chain reaction (qRT-PCR) technique. Four miRNAs were evaluated, i.e., miR-21, miR-29c, miR-141, and EBV-
miR-BART7. The results were normalized against a reference gene, miR-16. 
Result: A total of 52 patients and 10 normal subjects were enrolled in this study; 17 of them completed treatment. 
Patients’ mean age was 45.1+12.53 (14-68) years. The ratio between men and women was 3:1. MiR-21 and 
miR-29c could be detected in all subjects; miR-141 was detected in 22 (42.3%) and EBV-miR-BART7 in 26 
(50%) subjects. There was no significant difference between miR-21 or miR-29c expression between before and 
after therapy. However, miR-21 expressions tend to decrease in a patient with complete response (CR) 
(4.13+3.65 vs. 2.74+3.23; p=0.650) and tend to increase in patients with partial response (PR) (3.00+5.86 vs. 
8.77+8.43; p=0.465). There was no difference of miR-29c expression between CR and PR patients.  
Conclusion: Our study shows that not all miRNA can be detected in the plasma of NPC patients. Levels of 
miRNA expressions in these locally advanced patients are similar. Expression of miR-21 is potentially used as 
a biomarker of evaluating treatment response in NPC patients. 
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1. INTRODUCTION 
Nasopharyngeal carcinoma (NPC) is cancer with a unique distribution. In 
2008, more than 84,000 new cases occurred annually, representing about 0.7% 
of all cancers worldwide.  Southern China and Southeast Asian countries, 
including Indonesia, are regions with the highest incidence of NPC [1]. In 
Indonesia, NPC is the most frequent head and neck cancer with male 
predominance and affects patients in their young [2]. 
NPC is radiosensitive cancer, but 60% to 70% of patients came in advanced 
stage due to unspecific symptoms [3]. Because of the final anatomical structure 
of nasopharynx, monitoring of treatment results and recurrences are often not 
optimally achieved; therefore, non-invasive and specific biomarkers are essential 
to identify high-risk individuals and predict treatment response.  
One of the most studied biomarkers in the world is the expression level of 
plasma microRNA started in 2006. MicroRNA (miRNA) is a small, non-coding 
RNA molecule-sized 20-22 nucleotides, which regulates the expression of many 
genes post-transcriptionally. MiRNA is an important regulator of various cellular 
processes, including cell proliferation, differentiation, apoptosis, survival, 
motility, and morphogenesis. 
In a search for an effective biomarker in NPC, it tested three human miRNA 
and one EBV miRNA that has been studied elsewhere with convincing results. 
MiR-21 is one of the most extensively studied miRNA. Its expression is 
initiated by hypoxia and is upregulated in many cancers [4]. MiR-21 acts as an 
oncomir because of its capability to inhibit tumor suppressor genes, induce tumor 
growth, invasion, and metastasis [5, 6]. 
The mir-29c expression is down-regulated in NPC tissues and metastasis. It 
has a tumor suppressor effect through its effect on the extracellular matrix [7]. MiR-
141 was reported to be up-regulated in NPC tissues when compared to normal 
nasopharyngeal epithelia and may affect cell cycle, apoptosis, cell growth, 
migration and invasion of NPC cells [8]. MiR-BART7 was one of Epstein-Barr 
virus (EBV)-derived miRNAs, which were reported to be overexpressed in the 
plasma of undifferentiated NPC patients compared to healthy individuals [9]. 
This study was aimed to evaluate the expression of miR-21, miR-29c, miR-
141 and miR-BART7 in the plasma of NPC patients and to explore their 
relationship with clinical characteristics and treatment response.  
2. MATERIAL AND METHODS 
2.1 Study design and subjects 
The study design was a longitudinal cohort study in NPC patients in 
Dharmais Cancer Hospital (DCH) between December 2013 and May 2015.  
Subjects were recruited from ENT Department, Dharmais Cancer Hospital 
((DCH), whereas plasma miRNA expressions were assessed in the Biomolecular 
Laboratory of the Faculty of Medicine, Gadjah Mada University, Yogyakarta. 
Diagnosis of NPC was confirmed histopathologically from biopsy specimens of 
nasopharyngeal exploration.  
2.2 Preliminary study to find a reference gene 
Before evaluating miRNA expressions in true clinical patients, it has 
been performed a preliminary study to set laboratory protocols and to select 
a reference gene. Plasma specimens were obtained from several patients and 
were tested for miR-16, miR-21, miR-145, miR-155, and U6 small nuclear 
(sn) RNAs. Methods of RNA extraction and miRNA expression 
quantification were given in detail below. Amplification curve, melt curve, 
and melt peak of each miRNA were obtained and analyzed. 
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2.3 RNA extraction and quantitative real-time polymerase chain 
reaction 
Five mL of blood specimens were drawn from NPC patients and healthy 
subjects and stored in EDTA-containing vacutainers. Blood specimens were 
centrifuged to obtain the plasma and then were stored at -80oC before 
further processes. 
Total plasma RNA was extracted using a commercial kit (miRCURY 
RNA Isolation Kit-Biofluid, Exiqon, USA) following the manufacturer’s 
protocol. After isolation, RNA was reversely transcribed to cDNA using 
Universal cDNA Synthesis Kit II, 8-64 rxns, Exiqon, USA). Samples were 
then amplified and quantified using the real-time polymerase chain reaction 
(qRT-PCR) technique (ExiLent SYBR Green Master Mix, 2.5 mL, Cat. No. 
#203402, Exiqon, USA). Identification of miRNA sequence was done using 
commercial kits (miRCURY LNA LNA™ Universal RT microRNA PCR, 
Exiqon, USA) as follows: 
 
Table 1. Identification of miRNA sequence 
 
Process miRNA sequence 
hsa-miR-16-5p with target 
sequence 5’-3’ 
UAGCAGCACGUAAAUAUUGGCG 
hsa-miR-21-5p with target 
sequence 5’-3’ 
UAGCUUAUCAGACUGAUGUUGA 
hsa-miR-29c-3p with 
target sequence 5’-3’ 
UAGCACCAUUUGAAAUCGGUUA 
has-miR-141with target 
sequence 5’-3’ 
UAACACUGUCUGGUAAAGAUGG 
EBV-miR-BART7-3p with 
target sequence 5'-3' 
UUCUCCGAACGUGUCACG 
Analysis of the amplification curve was done with BioRad CFX 
Manager software to obtain the quantitative cycle (Cq), quantification curve, 
and melting curve. The Cq value of each miRNA is then normalized to the 
reference gene to obtain the difference of Cq (ΔCq). The relative expression 
level (fold change) of NPC patients and normal subjects was calculated after 
the Livak’s equation, Fold Change=2-ΔΔCq [10]. 
2.4 Treatment and evaluation 
The standard treatment of locally advanced NPC is chemoradiation. 
Patients received external radiation and concurrent chemotherapy with 5-
FU and cisplatin. External radiation was given 5 days a week using a 
fractionated dose of 200 cGy each day for a total of 6600 cGy. Treatment 
response was evaluated at week-12 after treatment by performing a physical 
examination and computed tomography (CT) scanning. 
3. RESULT 
3.1 Selecting a reference gene 
Preliminary results showed that miR-16, miR-21, and miR-155 were 
expressed in all plasma samples, while miR-145 and U6 snRNA were 
expressed at very low levels (graphic 1). MiR-16 was consistently showed 
good amplification curve and melted peaks among all samples; therefore, 
miR-16 was chosen as a reference for data normalization. 
3.2 Characteristics of the study subjects 
A total of 52 patients and 10 normal subjects were enrolled in this study 
initially. Due to a limited radiotherapy facility, only 17 patients could be 
treated immediately after diagnosis. Patients’ mean of age was 45.1+12.53 
years, ranging from 14 to 68 years old (table 1). 
3.3 Expression levels of selected miRNAs  
MiR-21 and miR-29c were detected in all subjects (figure 2), whereas miR-
141 (figure 3) was detected in 22 (42.3%) patients and EBV-miR-BART7                
(figure 4) in 26 (50%) patients. The expression of all miRNA did not achieve 
statistical significance. The fold change of each miRNA was 0.37 for miR-21; 
0.72 for miR-29c, 1.07 for miR-141, and 0.30 for miR-BART7 (table 2).  
The levels of miRNA expressions were similar across the disease stage 
(table 3). There was no significant difference of expression of miR-21 or miR-
29c between baseline and after standard therapy in 17 patients receiving 
chemoradiation (table 4). However, miR-21 tended to decrease in patients with 
CR and tend to increase in patients with PR (table 5 and graphic 5). There was a 
tendency that miR-29c was increased in PR patients (table 5 and graphic 6). 
4. DISCUSSION 
Plasma miRNA expressions have never been studied in Indonesia. This 
study is the first attempt to detect plasma miRNA in true clinical settings; in 
which, patients were prospectively followed from diagnosis to follow-up visits 
after definitive treatment.   
It was successfully identified miRNA expression in plasma samples from 
NPC patients and normal subjects. However, while miR-21 and miR-29c were 
expressed in all subjects, miR-141 and miR-BART7 were expressed only in 
some of the patients in very small quantities (Cq>35). 
Based on the literature study, miR-21, miR-141, and miR-BART7 are                                 
up-regulated and miR-29c is down-regulated in NPC patients compared to healthy 
persons. Our results showed different findings; plasma miR-21 and miR-BART7 were 
down-regulated, while miR-29c was only slightly down-regulated and miR-141 did 
not differ between NPC patients and normal subjects. However, the difference did not 
achieve clinical and statistical significance (fold change less than 2). 
Research on miRNA expressions in NPC has just been performed in less 
than a decade with different results. One study using U6 as an internal control 
showed that miR-16 and miR-21 were the most expressed miRNA in plasma 
(with a fold change of 28.86 and 6.64, respectively) [11]. In addition, they found 
that the fold change of miR-29c and miR-141 were 0.124 and 1.140, which were 
quite similar to our results.  
The difference in the results could be due to the use of an internal reference gene. 
Previous NPC studies used U6 while this study used miR-16 as an internal control. 
MiR-16 was chosen because our preliminary test showed its consistent expression in 
all samples, whereas the expression of U6 was very low (figure 1). This study is the 
first to use miR-16 as a reference gene in the plasma of NPC patients. 
MiR-16 and U6 are the most frequent reference genes for internal control of 
miRNA expression. However, both genes have some limitations. The concentration 
of miR-16 was vulnerable to hemolysis and could increase Cq [12]. Recent studies 
in 80 patients (20 patients in each with gastric, nasopharyngeal, colorectal, and 
breast cancers) showed that there was a large fluctuation of U6 expression because 
it was unstable during freezing and thawing process [13]. 
The study of miRNA expression is still in its infancy, and the results are often 
inconsistent. Our study showed that miR-21 expression was not increased and no 
other study could confirm our finding. However, under-expressed miR-21 might 
not be reported. In a study with 270 miRNA from NPC tissues, there was no 
report on miR-21 status, whether it was up- or down-regulated [14]. It might not 
be analyzed due to very low concentration (Cq>35) or fold change <2. 
There was no difference in miRNA expression among stage II, III, and IV 
patients. In this study, there was no patient in stage I found, while patients with 
distant metastasis (stage IVC) were not enrolled. The similar miRNA expression 
levels among patients stage II, III, and IV indicated that at the molecular level, these 
patients are homogeneous. It is possible that miRNA expressions are different 
during the early carcinogenesis process or after distant metastasis occurs.  
Study reports evaluating the relation between miRNA expression and disease 
stage are scarce. One of the earliest studies was the difference of miR-21 expression 
level between stage I and stage II-III breast cancer. In that study, the investigators 
found a higher expression of miR-21 in stage II-III and in patients with nodal 
metastasis [15]. In NPC patients, the expression of tissue miR-21 is over-expressed 
in stage III-IV patients, in patients with nodal metastasis and distant metastasis [16]. 
However, a study using plasma samples of 217 NPC patients showed different 
results. The expression of miR-21 tended to decrease as the tumor size increased 
(Spearman r=-0,159; p=0,019) and nodal status increased (Spearman r=-0,160; 
p=0,018) [11]. There was no correlation between miR-21 expression and disease 
stage based on the TNM system Spearman r=-0,130; p=0,056). Their results 
suggest that miR-21 plays a role at the early stage of the disease [11].  
Many studies of miRNA expressions in NPC were associated with distant metastasis 
and survival. Among the earliest study was the expression of miR-29c, when its down-
regulation was associated with metastatic event [7]. MiR-29c could suppress invasion and 
metastasis by increasing the expression of its target, i.e., the T-cell lymphoma invasion and 
metastasis 1 (TIAM) 1 gene [17]. Other study found that lymphatic invasion and 
advanced TNM stage were correlated with the level of plasma miR-9. The expression 
level of miR-9 could distinguish locoregional NPC cases from metastatic NPC with high 
sensitivity and specificity [18]. A recent study reported that a combination of four 
miRNAs (miR-22, miR-572, miR-638, and miR-1234) could differentiate NPC stage 
and has a better prognostic role than the TNM system [19]. 
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A recent study showed that the tissue level of EBV-miR-BART7 is 
positively related to the degree of lymph node involvement (N stage of the TNM 
system) and clinical stage of NPC. The mechanism by which miR-BART7 could 
be responsible to disease progression was shown in vitro when it specifically 
targets the phosphatase and tensin homolog (PTEN) gene, a major human tumor 
suppressor gene regulating the PI3K/AKT signaling pathway [20]. 
This study found no significant difference between miR-21 and miR-29c 
expression between before and after treatment. However, there was a tendency 
that the miR expression level was higher in patients with PR compared to CR. In 
addition, miR-21 expression tended to increase in PR and tend to decrease in CR 
patients, while miR-29c tended to increase in patients with PR. 
Early experiments in NPC cells (CNE line) showed 44 miRNAs were 
expressed after a chemotherapy course with 5-FU and cisplatin, including miR-
16, miR-21, and miR-29c. It was concluded that chemotherapy could alter 
miRNA profiles. However, almost all miRNAs, except miR-29a and 29-c, were 
also expressed by normal cells [21]. A recent study tested miR-21 on irradiated 
NPC cells (CNE-2 line). The experiment showed that miR-21 was among the 
most up-regulated miRNA in radioresistant cells. Radiosensitivity will increase 
after miR-21 was down-regulated [22]. 
An experimental study showed that mir-29c knockdown might cause 
resistance to radiotherapy and cisplatin chemotherapy through the up-regulation 
of antiapoptotic proteins Mcl-1 and Bcl-2. Therefore, miR-29c expression is 
needed to obtain a treatment response [23]. 
Comparing miRNA expression level before and after treatment represents how 
the body responds to a therapeutic intervention on an ongoing neoplastic process. 
However, it seems that single miRNA expression is insufficient to predict treatment 
response. A combination of several miRNAs might give a better prediction. For 
example, a study using deep sequencing technique found a combination of 4 
miRNAs (miR-483-5p, miR-103, miR-29a, and let-7c) as miR-signature to predict 
5-year survival of NPC patients [24]. That study select miRNA of a panel that 
included 146 human miRNAs, 51 new miRNAs, and 95 EBV-miRNAs. In another 
study, the investigators found a different miRNA set to predict NPC patients’ 
survival, i.e., miR-22, miR-572, miR-638, and miR-1234 [19]. Both of the studies 
above have been validated in their institutions; therefore, it is unlikely that their 
results are a coincidence. None of these studies use miR-21 or miR-29c, which has 
been widely evaluated previously. Altogether, results from various miRNA studies 
in NPC might show the complexity of nasopharyngeal carcinogenesis and their 
alterations after therapeutic intervention.  
There are some limitations to our study. First, we only included four selected 
miRNAs without a pilot study. These miRNAs were selected based on previous 
reports with convincing results on their roles in NPC patients. Second, the limited 
number of patients receiving standard treatment is insufficient to draw a firm 
conclusion on the role of miR-21 and miR-29c as predictors of treatment response. 
However, the results could give a foundation for further research on how to use 
miRNA expression in clinical settings. Third, the use of miR-16 as a reference gene 
could be bias because it could also be up-regulated in NPC patients [11]. Data 
normalization by comparing the amount of RNA included in the RT-PCR might not 
be right because RNA content in the plasma or serum varies according to the 
physical or pathological condition of the patient. Currently, there is no verified 
housekeeping gene in the blood that can be used for normalization [25]. 
5. CONCLUSION 
From the study results, it can be concluded that miR-21 and miR-29c 
are expressed in all NPC patients, but miR-141 and miR-BART7 are only 
expressed at very low levels in some of the patients. The levels of miRNAs’ 
expression are almost similar among stage II, III, and IV patients suggesting 
that at the molecular level, locally advanced NPC are homogenous. The 
expression of miR-21 is potentially used as a biomarker to monitor the 
treatment response of NPC patients. 
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APPENDICES 
 
A. TABLES 
Table 1. Characteristics of the study subjects (n=52)  
Variable 
NPC patients 
(n=52) 
Normal subjects  
(n=10) 
Age, years (mean+SD) 45.1+12.53 38.7+14.36 
Male gender (n, %) 34 (65.4%) 6 (60.0%) 
Stage (n, %)   
IIB 8 (15.4%) - 
III 16 (30.8%) - 
IVA 13 (25.0%) - 
IVB 15 (28.8%) - 
Histopathology (n, %)   
Squamous cell carcinoma 2 (3.8%) - 
Undifferentiated carcinoma 50 (96.2%) - 
Table 2. Expression of plasma miRNA between NPC and normal subjects 
miRNA NPC (n=52) Normal (n=10) P Value Fold Change 
miR-21 2.90±2.71 1.49±0.96 0.110a 0.37 
miR-29c 7.24±1.68 6.76±2.72 0.544a 0.72 
miR141 11.35 (3.42-14.46) 11.29±2.66 0.743b 1.07 
miRBART7 11.23±3.22 9.47±6.00 0.340a 0.30 
 a t-test;  
 b Mann-Whitney U test 
Table 3. Expression levels of plasma miRNA in NPC patients based on 
disease stage 
 
Stage II 
(n=7) 
Stage III 
(n=17) 
Stage IV 
(n=28) 
P* 
miR-21 3.52+2.00 1.85+1.43 3.38+3.27 0.150 
miR-29c 7.24+0.83 7.16+1.68 7.28 +1.87 0.977 
miR-141 12.53+1.80 11.37+1.89 10.59+2.61 0.356 
miR-BART7 12.51+2.92 11.44+3.21 10.90+3.41 0.734 
 c one-way ANOVA 
Table 4. Comparison of miRNA expression levels in NPC patients 
between before and after treatment (n=17) 
miRNA 
Before 
Treatment 
After 
Treatment 
P*  Fold change 
miR-21 (mean+SD) 3.86+4.08 4,16+5,30 0,981 0,98 
miR-29c (mean+SD) 7.00+1.68 7,33+2,61 0,287 0,80 
c  Wilcoxon’s signed ranks test; SD=standard deviation 
Table 5. Comparison of miRNA expression levels between NPC patients 
with complete response (CR) and partial response (PR) 
 Complete Response 
(n=13) 
Partial Response  
(n=4) 
miR-21 before treatment (mean+SD) 4.13+3.65 3.00+5.86 
miR-21 after treatment (mean+SD) 2.74+3.23 8.77+8.43 
p value*  0.650 0.465 
miR-29c before treatment (mean+SD) 6.76+1.70 7.80+8.93 
miR-29c after treatment (mean+SD) 6.84+2.66 8.93+1.90 
p value* 0.701 0.068 
c Wilcoxon’s signed ranks test; SD = standard deviat 
 
B. GRAPHICS 
Graphic 1. The amplification and melt curves of miR-16, miR-21, miR-
155, and U6 during the preliminary study to select a reference gene 
 
 
 
 
 
Graphic 2. The amplification and melt peak curves of miR-21 (red) and 
miR-c (blue) in nasopharyngeal cancer patients 
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Graphic 3. The expression of miR-141 after the 30th cycle 
Graphic 4. The expressions of miR-BART7 in NPC patients (dark green) 
compared to miR-BART7 in normal subjects (blue) and to the reference 
gene miR16 (light green).  
 
Graphic 5. The expression levels of miR-21 in patients treated with chemoradiation  
 
 
 
 
 
 
 
Graphic 6. The expression levels of miR-29c in patients treated with chemoradiation  
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